![](https://static.wixstatic.com/media/230099_323b147901ac481da06858384dac7b6f~mv2.png/v1/fill/w_56,h_32,al_c,q_85,usm_0.66_1.00_0.01,blur_2,enc_auto/230099_323b147901ac481da06858384dac7b6f~mv2.png)
Researchers at EARA member the University of Padova, Italy, have found a potential target for early treatment of kidney inflammation caused by lupus.
Lupus - an autoimmune disease - occurs when the body’s immune system attacks its own tissues and organs. One of the most sever organ manifestations of this condition is lupus nephritis, a type of kidney disease that could lead to kidney failure.
The team used mice to understand the role of Pentraxin3 (PTX3) – a molecule known to be unbalanced in human lupus.
They found that mice immunised with PTX3 developed a protective immunity, preventing them from developing overt lupus nephritis, and improving overall survival.
“Animal research allows us to make crucial advances when dealing with rarer conditions in which targeted treatments - instead of lifelong dependence on drugs - are paramount for a better outcome in terms of both survival and the quality of life of our patients.”
Mariele Gatto, MD, PhD, Unit of Rheumatology, Padova University